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Understanding tolerance mechanisms at the cellular and molecular level holds the promise
to establish novel immune intervention therapies in patients with allergy or autoimmunity
and to prevent transplant rejection. Administration of mAb against the CD4 molecule has
been found to be exceptionally well suited for intentional tolerance induction in rodent
and non-human primate models as well as in humanized mouse models. Recent evidence
demonstrated that regulatory T cells (Treg) are directly activated by non-depleting CD4
ligands and suggests Treg activation as a central mechanism in anti-CD4-mediated tol-
erance induction. This review summarizes the current knowledge on the role of Treg in
peripheral tolerance, addresses the putative mechanisms of Treg-mediated suppression
and discusses the clinical potential of harnessing Treg suppressive activity through CD4
stimulation.
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REGULATORY T CELLS IN MAINTENANCE OF
PERIPHERAL TOLERANCE
The notion of peripheral immune regulation by T cells that
shut off other immune cells has been around for many decades
(Gershon andKondo, 1971). Discovery of suitable surfacemarkers
(Sakaguchi et al., 1995; Takahashi et al., 1998) and a lineage-
speciﬁc transcription factor (Hori et al., 2003; Walker et al., 2003)
conﬁrmed the existence of a distinct regulatory T cell (Treg)
population. Originally identiﬁed by their aptitude to hold off
autoimmune reactions (Sakaguchi et al., 1995; Takahashi et al.,
1998; Wildin et al., 2002; Fontenot et al., 2005), Treg own far-
ranging suppressive activity affecting the function, maturation,
and survival of all types of immune cells (Thornton and She-
vach, 1998; Jonuleit et al., 2001; Grossman et al., 2004; Kojima
et al., 2005) in response to self and non-self antigens, including
pathogens (Belkaid et al., 2002; Hasenkrug, 2003). Additionally,
Treg have been shown to confer regulatory properties upon sup-
pressed T cells implementing a second layer of regulation (Jonuleit
et al., 2002; Stassen et al., 2004; Andersson et al., 2008).
Attempts to deﬁne the molecular basis of Treg suppression
have lead to the description of numerous putative pathways and
molecules (Tang and Bluestone, 2008; Shevach, 2009). A majority
of studies agreed on cell contact-dependent suppression by Treg
in vitro (Thornton and Shevach, 1998; Jonuleit et al., 2001) and the
observation of persistent contacts between Treg and dendritic cells
(DCs) during active suppression by intravital microscopy suggests
that cell contact-dependent suppression might also play a role
in vivo (Tang et al., 2006).
Analyzing themolecularmechanismof contact-dependentTreg
suppression by comparison of gene expression in Treg and non-
regulatory T cells, we found that Treg up-regulate cAMP in their
cytosol upon activation and consign cAMP to conventional CD4+
T cells and DCs (Bopp et al., 2007; Becker et al., 2009; Fassbender
et al., 2010) by gap junction intercellular communication (GJIC;
Oviedo-Orta et al., 2000). Upon transfer cAMP inhibits the pro-
liferation and differentiation of responder cells, most probably
through the induction of inducible cAMP early repressor (ICER)
expression (Foulkes et al., 1991; Bodor et al., 1996, 2007). Con-
tinuative work revealed that cAMP transmission is an essential
component of Treg-mediated suppression in vivo (Bopp et al.,
2007; Becker et al., 2009). Concurrent with stable and persistent
Treg–DC interaction (Tang and Bluestone, 2006), transfer of Treg-
derived cAMP into conventional T cells in vivo was inevitably
dependent on the presence of antigen presenting cells (APC) and
restricted to the draining lymph node (Bopp et al., 2007). Corre-
spondingly, repression of cAMP accumulation in Treg either by
adenylyl cyclase inhibition, application of a cAMP-speciﬁc antag-
onist or phosphodiesterase (PDE) overexpression abrogated Treg
suppression (Bopp et al., 2007; Oberle et al., 2007; Becker et al.,
2009; Klein et al., 2012; Martin et al., 2012). Inversely, blockade
of cAMP degradation by PDE inhibition improved Treg-mediated
suppression in a murine asthma model (Bopp et al., 2009).
Regarding cAMP regulation in Treg, Foxp3 has been shown
to repress PDE3b expression (Gavin et al., 2006) thereby pre-
venting cAMP degradation. More recently, Huang et al. (2009)
showed that the high cAMP content in Treg and their sup-
pressive property depend on Foxp3-mediated repression of the
adenylyl cyclase 9 (AC9) regulating miRNA 142-3p. In line
with these observations, Lahl et al. (2009) demonstrated that
non-functional Treg in Foxp3 mutant scurfy mice harbor signiﬁ-
cantly reduced levels of cytosolic cAMP. Hence, the transcription
factor Foxp3 participates in cAMP buildup by concomitantly
regulating the expression of cAMP-generating and degrading
enzymes. It is noteworthy that the transmission of cAMP is
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actually involved both in the suppression of other T cells (Bopp
et al., 2007; Becker et al., 2009; Huang et al., 2009; Klein et al.,
2012) and in suppression of DCs (Fassbender et al., 2010).
Together these ﬁndings classify cAMP as a key component of Treg
suppressive mechanism in vitro and in vivo and disclose cAMP-
regulating enzymes as molecular targets for therapeutic interven-
tion with Treg activity in pathological processes like allergy and
autoimmunity.
Next to the transfer of cAMP through gap junctions, produc-
tion of extracellular adenosine has been suggested as an alternative
mechanism in cAMP-dependent suppression by Treg (Deaglio
et al., 2007). Extracellular nucleotides are anti-inﬂammatory
mediators produced by a variety of cell types including Treg
(Deaglio et al., 2007; Mandapathil et al., 2009) and Th17 cells
(Chalmin et al., 2012). Physiologically, extracellular nucleotide
production represents a protective mechanism in response to
tissue injury (Fredholm, 2007). In Treg suppression adenosine
formation through the ectoenzymes CD39 and CD73, expressed
by murine Treg and a subpopulation of human Treg (Mandap-
athil et al., 2009), has been assumed to induce cAMP production
in conventional T cells or DCs upon binding to the A2A recep-
tor (Deaglio et al., 2007; Ernst et al., 2010). However, the role of
adenosine as amajor suppressivemechanismemployed speciﬁcally
by Treg is questionable. Blockade of cAMP production in respon-
der T cells by inhibition of adenylyl cyclases does not alter their
susceptibility to Treg-mediated suppression (Klein et al., 2012). In
addition, A2A receptor expression is detectable on T cells 4 days
after stimulation (Deaglio et al., 2007) while T cells are suscep-
tible to Treg suppression exclusively within the ﬁrst 24 h after
stimulation (Hagness et al., 2012). Finally, Blockage of ectonu-
cleotidase activity only slightly abrogates suppression of human
T cells by CD39 expressing Treg (Mandapathil et al., 2010). Thus,
while nucleotides certainly affect numerous cellular functions –
including de novo cAMP generation in Treg – their role in Treg
suppression is most likely of an indirect nature.
Interestingly, cAMP up-regulation in Treg coincides with
another cell contact-dependent mechanism of suppression: Treg
constitutively express the two co-inhibitory membrane-bound
molecules CTLA-4 and TIGIT (Read et al., 2000; Takahashi et al.,
2000) which are believed to provide inhibitory signals. In mice
CTLA-4 deﬁciency (Bachmann et al., 1999), CTLA-4 blockade
(Takahashi et al., 2000), and Treg-speciﬁc ablation of CTLA-4
(Wing et al., 2008) resulted in spontaneous autoimmunity. Yet,
CTLA-4 deﬁcient Treg remain suppressive in vitro and in vivo
(Tang et al., 2004; Read et al., 2006) suggesting additional mech-
anisms to be involved. Studies on human Treg in vitro revealed
only a minor role of CTLA-4 in Treg suppression (Birebent
et al., 2004) or ﬁrmly excluded CTLA-4 as a suppressive mech-
anism (Baecher-Allan et al., 2001; Jonuleit et al., 2001; Levings
et al., 2001). However, discrepancies regarding the importance
of CTLA-4 in Treg suppression might in part be due to the use
of different target cells. While the role of CTLA-4 in suppres-
sion of T cells remains uncertain, it is unequivocally required in
the suppression of APC. Suppression of DCs by Treg via CTLA-
4 has been shown to induce the downregulation of CD80 and
CD86 (Cederbom et al., 2000) preventing effector T cell acti-
vation by the APC in vitro (Oderup et al., 2006) and in vivo
(Wing et al., 2008). Notably, elevated cAMP levels in T cells
have been shown to increase CTLA-4 expression (Vendetti et al.,
2006) and cAMP and CTLA-4 expression are simultaneously
up-regulated in Treg upon activation (Becker et al., 2009).
While a majority of studies ﬁrmly excluded soluble factors in
Treg suppression in vitro, there is growing evidence that cytokines
substantially add to the immune regulatory function of Treg
in vivo. In particular, transforming growth factor-β (TGF-β) and
IL-10 seem to be indispensable for sustained tolerance induc-
tion by Treg. A role for TGF-β in maintenance of peripheral
tolerance was initially suggested by its importance in infectious
tolerance (Chen et al., 2003) particularly its long-lasting produc-
tionbyCD4+ Tcells from tolerantmice in long-termacceptance of
allografts (Daley et al., 2007). However, in order to exert its biolog-
ical functions, TGF-β needs to be converted from its latent (bound
to latency associated peptide, LAP) into its active conformation by
proteolytic cleavage (Khalil, 1999). Yet, there are multiple mecha-
nisms of activating TGF-β from its latency (Lawrence, 2001; Annes
et al., 2003) and it is unclear how TGF-β is activated in vivo.
Although repeatedly observed in disease models (Nakamura
et al., 2001) a direct contribution of TGF-β in Treg suppression
remained controversial because anti-TGF-β antibodies and sol-
uble TGF-RII failed to affect the suppressive function of Treg
(Andersson et al., 2008). Recently, “glycoprotein A repetitions
predominant” (GARP) expressed on the surface of Treg upon acti-
vation (Wang et al., 2008,2009; D’Alise et al., 2011) has been shown
to act as a receptor for the TGF-β/LAP complex (Stockis et al.,
2009). Reminiscent of infectious Treg suppression (Jonuleit et al.,
2002; Stassen et al., 2004) latent TGF-β bound toGARP on the sur-
face of activated Treg has been demonstrated to convert responder
T cells into inducedTreg (Andersson et al., 2008). Thus, apart from
acting as a soluble modulator of immune cells, TGF-β supposedly
helps Treg to execute their contact-dependent suppressive activity
by binding to GARP (Battaglia and Roncarolo, 2009).
IL-10has beenunequivocally shown to formanother important
mediator in Treg suppression in vivo (Kearley et al., 2005; Collison
et al., 2007) particularly in suppression of pathogenic Th17 cells
(Chaudhry et al., 2011; Huber et al., 2011). Correspondingly, Treg-
speciﬁc ablation of IL-10 leads to inﬂammation (Rubtsov et al.,
2008). In contrast to general Tregdeﬁciency, however, Treg-speciﬁc
IL-10 paucity leads to mucosal but not systemic autoimmunity,
suggesting mucosal restriction of IL-10-mediated Treg tolerance
induction. This view is supported by our previous observation
that human Treg expressing gut-homing β7 integrin preferen-
tially induce IL-10 production in converted secondary T helper
suppressor cells (Stassen et al., 2004).
Due to their far-ranging tolerizing capability Treg have become
key targets in the development of tolerance-inducing therapies
(Wing and Sakaguchi, 2010). Like other T cells, Treg require acti-
vation for their function. Attempts to exploit Treg for therapeutic
purposes therefore depend on Treg activation, either by antigen
or polyclonal stimulation (Jordan et al., 2001). Current efforts
to increase the frequency and potency of Treg in vivo include
the use of cytokines (Tawara et al., 2010), antigen targeting to
immature DC (Mahnke et al., 2003), and monoclonal antibodies
(mAb) against surface molecules (Belghith et al., 2003). As a whole
population Treg are biased toward recognition of self-antigens
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(Hsieh et al., 2004), however, because antigenic speciﬁcities of Treg
in diseases have not been elucidated, potential clinical applica-
tions have mainly focused on polyclonal Treg activation methods
(Horwitz et al., 2004).
CORECEPTOR ENGAGEMENT AND PERIPHERAL
TOLERANCE
Tcell surfacemolecules that participate inT cell receptor-mediated
stimulation have a signiﬁcant inﬂuence on T cell function. mAb
against coreceptors have been successfully shown to allow inten-
tional tolerance induction in rodent and non-human primate
models (Krieger et al., 1996). One particularly well-established
regimen of tolerance induction is the administration of anti-CD4
mAb (Waldmann and Cobbold, 1998). Although the mecha-
nisms underlying tolerization by anti-CD4 mAb are not yet fully
understood, the activationof Treghas been recognized as the enter-
ing wedge to successful tolerance induction (Becker et al., 2009;
Kendal et al., 2011; Martin et al., 2012).
CD4, a 55-kDa glycoprotein with four extracellular domains
(Littman, 1987), recruits the protein kinase p56lck (Rudd et al.,
1988; Veillette et al., 1988) to the TCR complex (Holdorf et al.,
2002; Kim et al., 2003; Nika et al., 2010) and strengthens the
contact betweenTcells andAPCs through its interactionwithnon-
polymorphic regions of MHC class II molecules (Greenstein et al.,
1984; Doyle and Strominger, 1987; Konig et al., 1992, 1995). CD4
molecules on T cell surface have been shown to preferentially form
disulﬁde-linked dimers and tetramers (110 and 220 kDa; Li et al.,
1998; Moldovan et al., 2002) andmutations disabling dimerization
completely abrogate its coreceptor function (Vignali and Vignali,
1999). CD4 expression on mature T cells is uniform with the
exception of polarized T helper 2 cells (Itoh et al., 2005) and Treg
(Bryl et al., 2001) which both show decreased CD4 expression sup-
posedly entailing altered proximal TCR signaling (Hannier et al.,
2002; Itoh et al., 2005; Tsang et al., 2006).
Through its interaction with tyrosine kinase p56lck , CD4
engagement alone can induce TCR-independent signaling events
in T cells (Zhou and Konig, 2003). Selective engagement of the
CD4 coreceptor by certain mAb raises intracellular calcium and
IL-2 production (Carrel et al., 1991), whereas other anti-CD4
mAb prime T helper cells to activation-dependent cell death trig-
gered by subsequent TCR/CD3-mediated signals (Newell et al.,
1990; Tamma et al., 1997). Comparing mAb against different
CD4 epitopes, Baldari and colleagues suggested that the gene-
activating and proapoptotic potential of different anti-CD4 mAb
may be associated with different epitopes (Baldari et al., 1995;
Di Somma et al., 1995; Milia et al., 1997). However, a similar
range of divergent responses can be induced through a single
CD4 epitope as demonstrated for the CD4-binding (Lasky et al.,
1987) human immunodeﬁciency virus-1 (HIV-1) envelope pro-
tein gp120 (Liegler and Stites, 1994;Westendorp et al., 1995; Masci
et al., 1999). It is therefore tempting to speculate that the func-
tional outcome of CD4-stimulation might mainly depend on the
functional state of the T cell addressed rather than on a speciﬁc
CD4 epitope. However, the functional state is believed to affect the
formation of CD4 oligomers, which, in turn, regulate the activa-
tion of the CD4 cytoplasmic tail-associated tyrosine kinase p56lck ,
by trans-phosphorylation (Veillette et al., 1989).
Even before the role of the CD4 molecule in T cell activa-
tion had been fully recognized, three groups reported that short
courses of anti-CD4 mAb application induce long-term tolerance
to foreign proteins (Benjamin and Waldmann, 1986; Benjamin
et al., 1986; Goronzy et al., 1986; Gutstein et al., 1986). Subsequent
studies revealed that anti-CD4-mediated tolerance induction was
not based on T cell depletion but rather an activation of regu-
latory mechanisms (Benjamin et al., 1988; Carteron et al., 1988,
1989; Qin et al., 1990). Further, tolerance could not only be
induced to foreign proteins but also to various transplanted allo-
grafts (Shizuru et al., 1987; Qin et al., 1989; Davies et al., 1996),
demonstrating that the tolerizing potential of anti-CD4 mAb is
not restricted to a particular type of antigen. Immunoregulatory
mechanisms initially suggested to operate in anti-CD4 induced
tolerance include a predisposure of developing T cells to selective
deletion, or anergy in the thymus (Arima et al., 1997); immune
deviation (Scully et al., 1997); receptor blockade (Fehervari et al.,
2002; Harding et al., 2002); modulation of CD4 expression
(Portoles et al., 1999); and transmission of negative signals
(Chirmule et al., 1999). However, none of these – not mutu-
ally exclusive – processes could reasonably explain the “infectious
tolerance” phenomenon (Qin et al., 1993). Rather than being sub-
missive, anti-CD4 induced tolerance relied on dominant immune
suppression by T cells activated in presence of the antibody. In
regard to the dominant suppressive T cell type in charge several
functionally and phenotypically different anti-CD4 mAb-induced
tolerogenic CD4+ T cell populations have been proposed (Bushell
et al., 2003; Chen et al., 2003; Cobbold et al., 2004; Karim et al.,
2005). However, whether these had been directly or indirectly
induced by anti-CD4 treatment remained undeﬁned at ﬁrst. The
impressive capacity of Treg and their ability to confer regulatory
properties upon suppressed T cells (Jonuleit et al., 2002; Stassen
et al., 2004; Andersson et al., 2008) in particular, strongly sug-
gested a role of Treg in anti-CD4-mediated “infectious tolerance”
induction. In support of this assumption administration of non-
depleting anti-CD4 mAb into mice had been shown to result in
pre-activation of Treg in vivo (Karim et al., 2005; Yang et al., 2007).
Eventually, using B6. Foxp3(hCD2) mice to ablate Treg with an
anti-hCD2 mAb Kendal et al. (2011) formally demonstrated that
Treg are crucial for infectious tolerance induced by non-ablative
anti-T cell mAb.
Motivated by the description of activated Treg in murine anti-
CD4 tolerance models we previously analyzed the effect of CD4
binding agents on human Treg. Comparing numerous anti-CD4
mAb we found that certain anti-CD4 mAb have the potential
to induce the suppressive function of isolated human Treg in
a supposedly T cell receptor-independent manner (Becker et al.,
2007). In addition, we and others observed that the CD4-binding
HIV-1 surface protein gp120 activates the suppressive function
of Treg (Nilsson et al., 2006; Kinter et al., 2007) in vitro and in
two humanized mouse models in vivo (Becker et al., 2009; Ji and
Cloyd, 2009) signifying that stimulation via the CD4 receptor
represents an efﬁcient Treg activating pathway with potential to
induce immunological tolerance in humans.
Difference between anti-CD4 mAb to trigger Treg suppressive
activity could not be related to a particular CD4 epitopes. How-
ever, comparing the Treg activating potential of different anti-CD4
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mAb and CD4 binding virus envelopes we observed that one cru-
cial event that separates Treg activating and non-activating CD4
ligands consists in up-regulation of the second messenger cAMP
(Becker et al., 2009 and unpublished results). Moreover, the bind-
ing afﬁnity of CD4 ligands seems to play a role as suggested by the
fact that weak CD4 binding viral envelopes from HIV-2 (gp105)
and SIV (gp130) did not activate human Treg in vitro and in vivo.
However, apart from these general observations the signaling
events initiated by separate ligation of CD4 on Treg so far remain
unexplored. In particular, it is unclear whether CD4 stimulation
of Treg is truly independent of TCR signals, whether and how both
pathways resemble or differ from another, and, most important,
whether CD4-mediated signals are differently or similarly han-
dled in Treg and conventional CD4+ T effector cells. The latter
question is of particular interest since Treg are believed to main-
tain an activated phenotype through constant stimulation by self
antigens, yet, require additional stimulation to become suppres-
sive. Future insights into how TCR and CD4 signaling pathways
drive the suppressive activity of Treg will undoubtedly help to
understand Treg biology and discover alternative intervention
points for functional manipulation of Treg suppressive activity.
As summarized in Figure 1 at least three different immune
mechanisms can be distinguished that help to explain the toleriz-
ing effect of CD4-speciﬁc agents: First, a general Treg-independent
mechanism that consist in interference with proper CD4 corecep-
tor function resulting in induction of T cell anergy or T cell deple-
tion (Figure 1A). This effect seems to depend either onCD4/MHC
class II binding blockade or additional TCR-independent signal-
ing. Second, by modulating antigenic stimulation, individual
CD4 mAb induce differentiation of naive T cells into adap-
tive Tregs (Oliveira et al., 2008), which are suggested to control
pathogenic effectors through TGF-β (Oliveira et al., 2011) or
IL-10 release (Figure 1B). Finally, and crucially important for
tolerance induction, CD4-speciﬁc mAb activate the suppres-
sive function of Treg (Becker et al., 2007; Kendal et al., 2011),
which, upon activation, exert control on pathogenic T cells
FIGURE 1 | Potential modes of tolerance induction by CD4-specific
monoclonal antibodies. A short-term treatment with non-depleting
CD4-speciﬁc mAb induces dominant tolerance to foreign proteins and
transplanted allografts. This ﬁgure represents the different immune
mechanisms that have been proposed to explain the tolerizing effect of
CD4-speciﬁc mAb. Three intervening points can be distinguished: (A) CD4
binding by non-depleting CD4-speciﬁc mAb modulates antigenic stimulation
through theT-cell receptor complex resulting in induction of T cell anergy.
(B) By modulating antigenic stimulation, CD4-speciﬁc mAb induce
differentiation of naive T cells into adaptive regulatory T cells, which control
pathogenic effectors through transforming growth factor-β (TGF-β) and IL-10
release. (C) Crucially important for tolerance induction, CD4-speciﬁc mAb
activate the (cAMP-dependent) suppressive function of Treg, which, upon
activation, exert control on pathogenicT cells by direct and linked suppression.
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by direct and linked suppression (Figure 1C). These different
effects of CD4 stimulation are intrinsic functions of individual
anti-CD4 mAb.
CLINICAL APPROACHES TO Treg-MEDIATED
TOLERANCE INDUCTION
Current immunosuppressive therapies are efﬁcient in prevent-
ing acute transplant rejection and dampening inﬂammation in
autoimmune diseases such as rheumatoid arthritis or lupus.
Nevertheless, immune suppression remains inadequate, as it
comprises signiﬁcant side effects such as organ toxicity and
hypersuppression disabling protective immune responses against
pathogens and enhancing the risk of chronic infections. Hence,
there is a clinical need for novel immunotherapeutic drugswith the
ability to rebalance the immunologic tolerance network without
persistently affecting immune function. In contrast to pharmaco-
logical immune suppression, re-induction of tolerance through
the exploitation of evolutionarily established tolerance mecha-
nisms is expected to offer a parentally operative cure. Among
mechanisms operative in self-tolerance, the immune-suppressive
activity of Treg appears to be exceptionally well suited for ther-
apeutic exploitation for several reasons: First, activated Treg
dampen the function of a wide range of immune cells includ-
ing T cells (Pandiyan et al., 2007), B cells (Lim et al., 2005),
DC (Misra et al., 2004; Larmonier et al., 2007), and monocytes
(Taams et al., 2005) and affect a broad range of immune con-
texts including cardiovascular disease (Ait-Oufella et al., 2006) and
obesity-induced insulin resistance (Feuerer et al., 2009). Second,
the activation of Treg is antigen-speciﬁc deﬁned by the selected
T cell receptor repertoire in the thymus. However, once activated
the suppressive mechanisms of Treg operate in an antigen-non-
speciﬁc manner, sidestepping the need to identify disease-speciﬁc
antigens to affect a particular Treg population. Prime examples of
the Treg immune dampening potential are experiments demon-
strating that Treg can be expanded and re-infused to limit immune
responses (Hoffmann et al., 2002) preventing GvHD induction
without causing toxicity. While persistent polyclonal Treg acti-
vation would lead to general immune hyporesponsiveness, a
short-term Treg activation – as established for tolerance induction
with non-depleting anti-CD4 mAb in mice – is expected to induce
(or re-induce) antigen-speciﬁc regulatory networks that main-
tain antigen-speciﬁc tolerance when Treg activity has returned to
normal levels.
Based on the evidence for Treg activation by CD4 ligands as
outlined above, anti-CD4mAb seem to represent ideal compounds
for Treg-mediated tolerance induction. However, although animal
studies have provided a compelling basis for clinical application of
anti-CD4-mediated tolerance induction, this approach has been
remarkably unsuccessful when transferred to the clinic. Although
short interventions with particular mAb have been shown to offer
quick symptomatic relief, improvements supposedly caused by
inactivation and depletion of CD4+ T cells (Kon et al., 2001;
Choy et al., 2002) remained transient. Failure to establish an anti-
CD4-based tolerogenic therapy in humans is most likely due to
difﬁculties in translating the timing and dosage used in animal
models for human application. Importantly, in contrast to animal
models, mAb are administrated at late disease stages in clinical
studies. Whereas the immature immune system seems to depend-
ably allow tolerance induction with anti-CD4 mAb, it seems more
difﬁcult to tolerize the experienced immune system in patients, in
part due to the presence of effector and memory T cells resistant
to the suppressive action of Treg (Yang et al., 2007). In fact, Treg-
based therapies have been found to be generally less effective in
models of autoimmune diseases.Wehrens et al. (2011) for example
observed that functionally active Treg failed to control hyperacti-
vated T effector cells in rheumatoid arthritis patients with ongoing
inﬂammation but prevented autoaggressive immune responses
in non-inﬂammatory arthritis. Impaired Treg suppression under
inﬂammatory conditions has beenmainly ascribed to the inﬂuence
of TNF-α, IL-1, and IL-6, which turn effector T cells resistant to
Treg-mediated suppression (Walker, 2009; Goodman et al., 2011).
Certainly, resistance to Treg-mediated suppression can be over-
come by blockade of IL-6 (Chen et al., 2009) and supposedly, the
beneﬁcial effects of anti-TNF-α treatment include a similar effect
too (Ehrenstein et al., 2004; Valencia et al., 2006). Thus, provided
Treg can be sufﬁciently activated in the host, their suppressive efﬁ-
ciency might depend on the disease stage, which strongly argues
for a combination of Treg enhancing strategies with biologicals
that reverse Treg resistance in autoaggressive T effector cells. As
exempliﬁed with anti-CD3 mAb already in the clinic evacua-
tion of T effectors cells and concomitant enhancement of Treg
activity can form a very effective treatment (Chatenoud and
Bluestone, 2007).
With regard to anti-CD4-mediated tolerance induction in
humans, it is important to emphasize again that anti-CD4 mAb
vary in their capacity to activate Treg (Becker et al., 2007) and
antibodies used in clinical trials so far have not been analyzed with
regard to their Treg activating potential. However, clinical trials
with Treg enhancing agents such as the anti-CD4 mAb Tregal-
izumab in rheumatoid arthritis have been initiated to investigate
the efﬁcacy of Treg-based anti-CD4-mediated tolerance induction
in patients with autoimmune diseases.
CONCLUDING REMARKS
In summary, polyclonal activation of Treg through their surface
molecules by biologicals that enhance their intracellular cAMP
level are effective to induce the suppressive function of Treg for re-
induction of tolerance in small animal models and in humanized
mice. It is therefore expected that polyclonal Treg activation forms
a rational for tolerance induction in humans. However, both the
exact conditions, efﬁciency in different stages of disease and coop-
eration with additional treatment regiments to diminish T effector
cells need to be thoroughly explored. Moreover differential signals
in Treg versus T effector cells are far from being clear. In addi-
tion to deepening our understanding of Treg biology investigation
of the latter holds the key to deﬁne alternative entry points for
therapeutic manipulation of Treg function.
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